Oral Pharmacologic Treatment of Type 2 Diabetes
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Endocrinology & Metabolism".
Deadline for manuscript submissions: closed (15 June 2024) | Viewed by 3744
Special Issue Editor
Interests: obesity; metabolic surgery; precision diabetology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We cordially invite you to participate as an author in this Special Issue of JCM on “Oral Pharmacologic Treatment of Type 2 Diabetes”.
Currently, there are 12 classes of glucose-lowering drugs (GLD) marketed in the world, and this number is expected to keep growing in the coming years. In addition, several weight-loss medications have a favorable effect on glycemic control in patients with T2DM and obesity. Therefore, T2DM therapy in the XXI century will require expert knowledge of the advantages and disadvantages of each available drug and the possibility of a rational combination based on phenotype, pathophysiology, and pharmacogenomics—in other words, precision diabetology.
Intensive glycemic control reduces microvascular complications of T2DM. As a consequence, despite not showing a clear beneficial effect on cardiovascular (CV) morbidity, the glucocentric strategy was established several decades ago as the dominant therapeutic model in all guidelines for the treatment of this disease. Most of our patients, however, show an increase in visceral fat, and they clearly benefit from an adipocentric strategy that simultaneously achieves enough weight loss to optimize glycemic control without hypoglycemia, reduces CV risk, and improves other obesity comorbidities. In fact, in recent years, several GLDs with weight-loss properties from two therapeutic families, GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter type 2 inhibitors (SGLT-2i), have shown a reduction in CV and renal morbidity and mortality in patients with T2DM. All types of SGLT-2i and one GLP-1RA (semaglutide) are available as oral drugs.
In summary, we are living in an exciting era in the pharmacological treatment of T2DM. We look forward to receiving your submissions to this Special Issue.
Dr. Juan José Gorgojo-Martínez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- type 2 diabetes
- oral glucose-lowering drugs
- weight-loss medications
- SGLT-2 inhibitors
- oral GLP-1 analogs
- metformin